AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 152 min read$RZLT

Rezolute Completes Enrollment In Phase 3 UpLIFT Study Of Ersodetug For Tumor Hyperinsulinism

Rezolute (RZLT) completed enrollment in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism, with topline results expected in mid-2026. The study aims to reduce intravenous glucose use in 16 patients. Earlier interim results showed 7 of 8 participants met the primary endpoint. RZLT stock closed at $4.23, up 3.07% in afterhours.

Original reporting
rttnews.com
Published Oct 15, 2026, 5:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 5:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Rezolute Completes Enrollment In Phase 3 UpLIFT Study Of Ersodetug For Tumor Hyperinsulinism — source image
Source · rttnews.com
Decision brief

The 30-second read

$RZLTNeutralMed
01

Why it matters

Enrollment completion reduces execution risk and sets a clear timeline for data readout, likely influencing short‑term price action.

02

Market read

First‑report trial milestone for a micro‑cap biotech; may trigger speculative buying ahead of December data.

03

What to watch

The single‑patient death and small trial size may temper optimism; reimbursement and market access for rare‑disease drugs remain uncertain.

Relevance 8/10Novelty 8/10Timing: now

Background

Rezolute is a clinical‑stage biotech focused on hyperinsulinism therapies. The upLIFT study targets a rare condition with high unmet need.

Company-level read

Ticker impact

$RZLTNeutralHigh confidence
Context

Rezolute completed enrollment in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism, a first‑report clinical‑trial milestone.

Expected impact

potential upside pressure as investors price in favorable Phase 3 data expectations

Evidence & confidence

The news is a primary disclosure of a pivotal trial milestone for a biotech; such events historically move shares on the prospect of efficacy data.

Market effects

Sector

adds a positive data point for the rare‑disease biotech segment, may lift peer sentiment.

Regional

U.S. biotech market sees modest uplift from trial progress.

Global

limited to investors tracking rare‑disease therapeutics.

Counterpoint

What could challenge this read

If the Phase 3 data disappoint, the stock could face a sharp decline despite the enrollment milestone.

Key entities

  • company
    Rezolute, Inc.

    Biotech developing ersodetug for tumor and congenital hyperinsulinism.

Read at source← All news

StoryRezolute completes enrollment in Phase 3 upLIFT trial of ersodetug

Related articles

OCT 14
$RZLTMedAI 8/10

Rezolute Completes Phase 3 Enrollment for ersodetug

Rezolute (RZLT) completed Phase 3 enrollment for ersodetug in tumor hyperinsulinism, with topline results expected in mid-December 2026. Interim data showed 7 of 8 participants met the primary endpoint. Analysts have a $12.00 price target and a Buy rating, while AI analyst Spark rates it Neutral due to financial performance and regulatory signals.

tipranks.com2 min
OCT 14
$RZLTLowAI 8/10

Rezolute completes enrollment in Phase 3 upLIFT; topline results expected mid-December 2026

Rezolute Inc. (RZLT) completed enrollment in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism, with topline results expected mid-December 2026. The study aims for a ≥50% reduction in glucose infusion rate. Earlier data showed 7 of 8 participants met the responder criterion. The company plans to continue expanded access and may advance indications in 2027 if results are favorable.

tradingview.com1 min
OCT 14
$RZLTMedAI 8/10

Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Rezolute, Inc. (RZLT) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism Topline results expected mid-December 2026 REDWOOD CITY, Calif., October 14, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare

SEC EDGAR 8-K2 min
OCT 14
$RZLTMedAI 8/10

Rezolute (RZLT) Completes Enrollment in Phase 3 Trial for Ersode

Rezolute Inc (RZLT) completed enrollment in its Phase 3 trial for ersodetug, a treatment for tumor-induced hyperinsulinism. The company expects topline results by mid-December 2026. Rezolute has no revenue, with a market cap of $409 million and a GF Score of 33/100, indicating financial stability but operational challenges. Insiders have shown confidence with net buying of $0.2 million over the past year.

gurufocus.com2 min
OCT 14
$RZLTLowAI 8/10

Rezolute completes enrollment in phase 3 tumor study

Rezolute Inc. (RZLT) completed enrollment in its Phase 3 study of ersodetug for tumor hyperinsulinism, with 16 participants. Topline results are expected in mid-December 2026. The study's primary endpoint measures a 50% reduction in glucose infusion rate. Seven of the first eight participants met the responder criterion, and the treatment has been well-tolerated. Rezolute plans to continue its expanded access program.

investing.com2 min
OCT 14
$RZLTLow

Seven of eight early participants needed at least half as much glucose through a vein. Results are expected mid-December.

Rezolute, Inc. (RZLT) announced the completion of enrollment in its Phase 3 upLIFT study for ersodetug, a treatment for tumor hyperinsulinism. Topline results are expected mid-December 2026. Earlier data showed 7 of 8 initial participants met the primary endpoint, reducing IV glucose needs by 50%. The company plans to continue its expanded access program for compassionate use.

stocktitan.net2 min